{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:19:02Z","timestamp":1788261542955,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasis is a chronic, recurrent, immune-mediated inflammatory skin disease in which the TNF\/IL-23\/IL-17 axis plays a central role in the maintenance of mature plaques. However, this classical framework does not fully explain the early immune events triggered by skin injury, barrier disruption, infection, and the release of self-nucleic acids. It also does not fully explain selected clinical phenotypes. Type I interferons (IFN-I) are inducible cytokines involved in antiviral defense and danger sensing that may shift from protective immune mediators to pathogenic inflammatory amplifiers in psoriasis-prone skin. Self-nucleic acids released after tissue injury can form immunostimulatory complexes with antimicrobial peptides such as LL37. These complexes activate innate immune responses and induce IFN-I production. This process can promote dendritic-cell maturation and amplify the IL-23\/IL-17 inflammatory pathway. This review presents IFN-I as a stage-dependent and phenotype-specific immune module that links early danger sensing to subsequent inflammatory amplification in psoriasis. We focus on the protective role of IFN-I in skin danger responses, LL37-mediated abnormal nucleic acid sensing, multicellular IFN-I skin signatures, the stage-specific integration of IFN-I with the IL-23\/IL-17 axis, and clinical contexts with increased IFN-I activity. Moreover, we briefly discuss the therapeutic significance of tyrosine kinase 2 as a convergence node for IL-23, IL-12, and IFN-I signaling. Defining the role of IFN-I across different lesion stages and clinical phenotypes may improve the immunopathological model of psoriasis. It may also provide a basis for disease stratification, response prediction, and individualized therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1924303","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:55:55Z","timestamp":1788260155000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Type I interferon in psoriasis: mechanisms and clinical implications"],"prefix":"10.3389","volume":"17","author":[{"given":"Chang","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongwei","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01440","article-title":"Type 1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J Exp Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"154605","DOI":"10.1016\/j.cyto.2018.11.022","article-title":"The influence of interferon on healthy and diseased skin","volume":"132","author":"Hile","year":"2020","journal-title":"Cytokine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090480","article-title":"Self-RNA\u2013antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8","volume":"206","author":"Ganguly","year":"2009","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cytogfr.2014.10.009","article-title":"An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17","volume":"26","author":"Grine","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.61973","article-title":"Role of interferon regulatory factor-mediated signaling in psoriasis","volume":"18","author":"Wang","year":"2021","journal-title":"Int J Med Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1694066","article-title":"Keratinocytes as active regulators of cutaneous and mucosal immunity: a systematic review across inflammatory epithelial disorders","volume":"16","author":"Klimitz","year":"2025","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jdermsci.2014.08.012","article-title":"Human skin dendritic cells in health and disease","volume":"77","author":"Haniffa","year":"2015","journal-title":"J Dermatol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.06.021","article-title":"Antimicrobial peptide LL37 and MAVS signaling drive interferon-\u03b2 production by epidermal keratinocytes during skin injury","volume":"45","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41467-019-13756-4","article-title":"Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis","volume":"11","author":"Herster","year":"2020","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00746","article-title":"Neutrophil extracellular traps promote inflammatory responses in psoriasis via activating epidermal TLR4\/IL-36R crosstalk","volume":"10","author":"Shao","year":"2019","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041275","article-title":"Interleukin-17A and keratinocytes in psoriasis","volume":"21","author":"Furue","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20963","article-title":"The biological basis of disease recurrence in psoriasis: a historical perspective and current models","volume":"186","author":"Puig","year":"2022","journal-title":"Br J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/24755303221127338","article-title":"Resident memory T cells in psoriasis: key to a cure","volume":"7","author":"Blauvelt","year":"2022","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04582.x","article-title":"Induction and exacerbation of psoriasis with interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases","volume":"27","author":"Afshar","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: classical vs. paradoxical. The Yin-Yang of TNF and type I interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14513","article-title":"Small plaque psoriasis re-visited: a type of psoriasis mediated by a type-I interferon pathway","volume":"31","author":"Khosravi-Hafshejani","year":"2022","journal-title":"Exp Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and Janus kinase\u2013signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20553","article-title":"Deucravacitinib in plaque psoriasis: four-year safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2 and long-term extension trials","volume":"39","author":"Armstrong","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-026-01779-x","article-title":"Risankizumab versus deucravacitinib in adults with moderate plaque psoriasis: 16-week results from the phase 4 IMMpactful trial","volume":"16","author":"Magnolo","year":"2026","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70251","article-title":"Dermatology 2.0: precision medicine for inflammatory skin diseases","volume":"40","author":"Di Domizio","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.immuni.2020.09.015","article-title":"Second-strand synthesis-based massively parallel scRNA-seq reveals cellular states and molecular features of human inflammatory skin pathologies","volume":"53","author":"Hughes","year":"2020","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1038\/s41467-023-39020-4","article-title":"Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis","volume":"14","author":"Ma","year":"2023","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1924303\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:55:56Z","timestamp":1788260156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1924303\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1924303"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1924303","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1924303"}}